| Completed | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid NCT05074472 | ZielBio, Inc. | Phase 1 / Phase 2 |
| Completed | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritone NCT02122185 | University of Chicago | Phase 2 |
| Completed | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube NCT02283658 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, NCT02101775 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid T NCT02142803 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavi NCT02111941 | Mayo Clinic | EARLY_Phase 1 |
| Completed | EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent O NCT01489371 | Gynecologic Oncology Group | Phase 1 |
| Withdrawn | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithe NCT01492920 | Gynecologic Oncology Group | Phase 3 |
| Completed | Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients Wi NCT01459380 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherap NCT01275664 | Gynecologic Oncology Group | N/A |
| Completed | TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients Wit NCT01294293 | Gynecologic Oncology Group | Phase 1 |
| Completed | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelia NCT01074411 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritone NCT01080521 | Gynecologic Oncology Group | — |
| Completed | Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallop NCT00993616 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Prim NCT00939809 | Gynecologic Oncology Group | Phase 2 |
| Completed | Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithe NCT00814086 | Gynecologic Oncology Group | Phase 1 |
| Completed | Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ova NCT00466960 | University of Washington | Phase 2 |
| Completed | Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carc NCT00357448 | University of Washington | Phase 1 |
| Completed | Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulkin NCT00079430 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in T NCT00085358 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopia NCT00060359 | Gynecologic Oncology Group | Phase 1 |
| Completed | Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma NCT00059787 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Research Study in Patients With Advanced Ovarian Epithelial Cancer NCT00053235 | Gynecologic Oncology Group | — |
| Terminated | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian NCT00004221 | Gynecologic Oncology Group | Phase 2 |
| Completed | Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stag NCT00002913 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Collecting Tumor Samples From Patients With Gynecological Tumors NCT00897442 | Gynecologic Oncology Group | — |
| Withdrawn | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tu NCT02050009 | Fox Chase Cancer Center | Phase 1 |